Table 1 The response analysis and survival time of all patients

From: Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial

 

All patients (n = 48)

Second-line (n = 31)

≥third-line (n = 17)

Best overall response, n (%)

CR

2 (4.2)

2 (6.5)

0 (0)

PR

12 (25.0)

8 (25.8)

4 (23.5)

SD

17 (35.4)

9 (29.0)

8 (47.1)

PD

17 (35.4)

12 (38.7)

5 (29.4)

ORR, % (95% CI)

29.2 (17.0–44.1)

32.3 (16.7–51.4)

23.5 (6.8–49.9)

DCR, % (95% CI)

64.6 (49.5–77.8)

61.3 (42.2–78.2)

70.6 (44–89.7)

mPFS (95%CI), months

4.0 (2.6–5.4)

4.0 (2.4–5.6)

3.8 (1.2–6.4)

mOS (95%CI), months

11.1 (5.7–16.5)

14.5 (8.4–20.6)

7.6 (5.4–9.8)